• news and publications | Enterprise Therapeutics | Treatment of respiratory diseases

PUBLICATIONS, NEWS & EVENTS

ECFS Clinical Meeting Liverpool TMEM16A potentiator

ECFS Clinical Meeting Liverpool TMEM16A potentiator

Objectives:…
October 9, 2019/by admin

A systematic comparison of the profiles of inhaled ENaC blocker candidates on mucociliary clearance: are we under-dosing in clinical studies?

A systematic comparison of the profiles of inhaled ENaC blocker…
October 9, 2019/by admin

Something old and something new: ENaC & TMEM16A as targets to hydrate mucus in the CF airway

Something old and something new: ENaC & TMEM16A as targets…
October 9, 2019/by admin

The pharmacology of novel TMEM16A potentiator compounds

The pharmacology of novel TMEM16A potentiator compounds

Henry…
April 2, 2019/by admin

TMEM16A channel function does not influence goblet cell numbers in the human airway epithelium

TMEM16A channel function does not influence goblet cell numbers…
April 2, 2019/by admin

EACT increases intracellular calcium levels by a TMEM16A-independent mechanism

EACT increases intracellular calcium levels by a TMEM16A-independent…
April 2, 2019/by admin

Enterprise Therapeutics strengthens leadership team, appoints Amit D. Munshi as Non-Executive Chairman

Appointment brings significant commercial pharma experience as…
March 25, 2019/by admin

Gordon Research Conference ‘Modeling and Targeting Mucociliary Function in Health and Disease: Genes to Cells to Interaction Networks and Tissues’ February 2019

Identifying pathways & compounds regulating goblet cell metaplasia…
February 20, 2019/by admin

Enterprise Therapeutics selected as a finalist for Scrip Awards and Lifestars Awards

Scrip Awards 2018 “Financing Deal of the Year- Private”…
October 4, 2018/by admin

32nd Annual North American Cystic Fibrosis Conference (NACFC) 18-20 October-Denver – Submission 210

Submission: 210 - PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE…
September 28, 2018/by admin

32nd Annual North American Cystic Fibrosis Conference (NACFC) 18-20 October-Denver – Submission 89

Submission: 89 - IDENTIFYING PATHWAYS REGULATING GOBLET CELL…
September 28, 2018/by admin

Enterprise Therapeutics raises £29 million ($41 million USD) funding

Brighton, UK – 12 April 2018: Enterprise Therapeutics Ltd (Enterprise),…
April 12, 2018/by admin

Enterprise is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity – the company plans to initiate clinical trials in 2019.

Scientific Strategy

Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.

Learn more

Pipeline

Enterprise has developed a pipeline of novel low molecular weight compounds with first in class potential – our most advanced compounds, which target ion channels in the airway epithelium are expected to enter human trials in late 2019.

Learn more